Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)

被引：0
|
作者：
Kiver, Verena [1 ]
Hamilton, Erika [2 ]
Tsurutani, Junji [3 ]
Curigliano, Giuseppe [4 ]
Martin, Miguel [5 ]
O'sullivan, Ciara [6 ]
Sohn, Joo Hyuk [7 ]
Tryfonidis, Konstantinos [8 ]
Santarpia, Libero [9 ]
Yang, Shan [9 ]
Dieras, Veronique [10 ]
机构：
[1] Charite Univ Med Berlin, Berlin, Germany
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan
[4] Univ Milan, European Inst Oncol, IRCCS, Milan, Italy
[5] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[6] Mayo Clin, Rochester, MN USA
[7] Yonsei Canc Ctr, Seoul, South Korea
[8] Merck & Co Inc, Rahway, NJ USA
[9] Seagen Inc, Bothell, WA USA
[10] Eugene Marquis Ctr, Rennes, France
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
762
引用
收藏
页码：39 / 39
页数：1
相关论文
共 50 条
  • [31] HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress).
    Krop, Ian E.
    Ramos, Jorge
    Zhang, Chiyu
    Hamilton, Erika P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): Outcomes by hormone receptor status
    Hamilton, Erika
    Reinisch, Mattea
    Loi, Sherene
    Okines, Alicia
    Pohlmann, Paula R.
    Brix, Eva Harder
    Bourgeois, Hugues
    Yeo, Belinda
    Aylesworth, Cheryl
    Cobleigh, Melody
    Goncalves, Anthony
    Moroose, Rebecca
    Tkaczuk, Katherine H. R.
    Tsai, Michaela
    Simmons, Christine
    Andersson, Michael
    Soliman, Hatem
    Cairo, Michelina
    Carey, Lisa A.
    Cameron, David
    Ramos, Jorge
    Feng, Wentao
    Oliveira, Mafalda
    CANCER RESEARCH, 2021, 81 (04)
  • [33] Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
    Murthy, R. K.
    Loi, S.
    Okines, A.
    Paplomata, E.
    Hamilton, E.
    Hurvitz, S. A.
    Lin, N. U.
    Borges, V.
    Abramson, V.
    Anders, C.
    Bedard, P. L.
    Oliveira, M.
    Jakobsen, E.
    Bachelot, T.
    Shachar, S. S.
    Mueller, V.
    Braga, S.
    Duhoux, F. P.
    Greil, R.
    Cameron, D.
    Carey, L. A.
    Curigliano, G.
    Gelmon, K.
    Hortobagyi, G.
    Krop, I.
    Loibl, S.
    Pegram, M.
    Slamon, D.
    Palanca-Wessels, M. C.
    Walker, L.
    Feng, W.
    Winer, E. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 597 - 609
  • [34] HER2CLIMB-04: Phase II trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+locally advanced or metastatic breast cancer with and without brain metastases
    Carey, L. A.
    Krop, I.
    Ramos, J.
    Feng, W.
    Hamilton, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S510 - S511
  • [35] Bevacizumab plus trastuzumab for treatment of HER2+metastatic breast cancer
    De Amuriza Chicharro, N.
    Gastalver Martin, C.
    Goyache Goni, M. P.
    Cortijo Cascajares, S.
    Garcia Munoz, C.
    Ferrari Piquero, J. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 984 - 985
  • [36] Tucatinib vs Placebo, Both Combined With Capecitabine and Trastuzumab, for Patients With Pretreated HER2-Positive Metastatic Breast Cancer With and Without Brain Metastases (HER2CLIMB)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 4 - 7
  • [37] Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)
    Murthy, Rashmi
    Loi, Sherene
    Okines, Alicia
    Paplomata, Elisavet
    Hamilton, Erika
    Hurvitz, Sara
    Lin, Nancy
    Borges, Virginia
    Abramson, Vandana Gupta
    Anders, Carey
    Bedard, Philippe L.
    Oliveira, Mafalda
    Jakobsen, Erik
    Bachelot, Thomas
    Shachar, Shlomit S.
    Mueller, Volkmar
    Braga, Sofia
    Duhoux, Francois P.
    Greil, Richard
    Cameron, David
    Carey, Lisa
    Curigliano, Giuseppe
    Gelmon, Karen
    Hortobagyi, Gabriel
    Krop, Ian
    Loibl, Sibylle
    Pegram, Mark
    Slamon, Dennis
    Palanca-Wessels, Maria Corinna
    Walker, Luke
    Feng, Wentao
    Winer, Eric
    CANCER RESEARCH, 2020, 80 (04)
  • [38] Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress)
    Heinemann, V.
    Bekaii-Saab, T.
    Van Cutsem, E.
    Tabernero, J.
    Siena, S.
    Yoshino, T.
    Nakamura, Y.
    Raghav, K.
    Cercek, A.
    Adelberg, D.
    Ramos, J.
    Yang, S.
    Andre, T.
    Strickler, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 159 - 160
  • [39] Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress)
    Heinemann, Volker
    Andre, Thierry
    Bekaii-Saab, Tanios
    Cercek, Andrea
    Nakamura, Yoshiaki
    Raghav, Kanwal
    Siena, Salvatore
    Strickler, John
    Van Cutsem, Eric
    Adelberg, David
    Ramos, Jorge
    Yang, Shan
    Yoshino, Takayuki
    Tabernero, Josep
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 60 - 60
  • [40] Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress)
    Fritsch, R.
    Andre, T.
    Bekaii-Saab, T.
    Cercek, A.
    Nakamura, Y.
    Raghav, K.
    Siena, S.
    Strickler, J.
    Van Cutsem, E.
    Adelberg, D.
    Ramos, J.
    Yang, S.
    Yoshino, T.
    Tabernero, J.
    SWISS MEDICAL WEEKLY, 2023, 153 : 70S - 70S
12345